1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4) 
L. Drgona, C. Gudiol, S. Lanini, B. Salzberger, G. Ippolito, M. Mikulska 
Clinical Microbiology and Infection 
Volume 24, Pages S83-S94 (June 2018)
DOI: /j.cmi
Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Mode of action of brentuximab vedotin, an antibody–drug conjugate targeting CD30. Upon binding to CD30 on the surface of the T-cell malignant cell, brentuximab vedotin is internalized via endocytosis. The exposure of protease-sensitive dipeptide linker to proteolytic lysosomal enzymes results in the release of monomethyl auristatin A (MMAE) molecules in the intracellular space. Binding of MMAE to tubulin disrupts the microtubule network, leading to induction of G2/M-phase cell cycle arrest and subsequent apoptosis.
Clinical Microbiology and Infection  , S83-S94DOI: ( /j.cmi )
Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions